SCHEMBL7965696

SCHEMBL7965696

CC(C)(C)OC(=O)N[C@H](CC(N)=O)C(=O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.56
KLK7 P49862 1/20 0.53
KLK5 Q9Y337 1/20 0.53
PPARG P37231 2/20 0.53
SYK P43405 1/20 0.53
CTSS P25774 3/20 0.53
CACNA1B Q00975 4/20 0.53
APP P05067 1/20 0.53
BACE1 P56817 4/20 0.52
CTSK P43235 2/20 0.51
CTSL P07711 1/20 0.51
CTSB P07858 1/20 0.51
TACR1 P25103 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7297130 1.00 PPARA (0.56) PPARAKLK7KLK5PPARGSYK
SCHEMBL1980647 0.90 PPARA (0.54) PPARAKLK7KLK5PPARGSYK
SCHEMBL1980648 0.90 PPARA (0.54) PPARAKLK7KLK5PPARGSYK
SCHEMBL6078485 0.90 SYK (0.56) PPARAKLK7KLK5PPARGSYK
SCHEMBL6078490 0.90 SYK (0.56) PPARAKLK7KLK5PPARGSYK
SCHEMBL12292731 0.90 BACE1 (0.51) PPARACTSSAPPBACE1CTSK
SCHEMBL5033775 0.90 PPARA (0.58) PPARAKLK7KLK5PPARGSYK
SCHEMBL1093029 0.90 PPARA (0.58) PPARAKLK7KLK5PPARGSYK
SCHEMBL3004720 0.90 PPARA (0.58) PPARAKLK7KLK5PPARGSYK
SCHEMBL22479161 0.89 PPARA (0.58) PPARAKLK7KLK5PPARGSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059214-A1 AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-02-20 US disclosed
US-20240398966-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2024-12-05 US disclosed
EP-4444727-A1 AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS Pretzel Therapeutics, Inc. (US) 2024-10-16 EP disclosed
US-11998610-B2 Conjugates and methods of using the same FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2024-06-04 US disclosed
WO-2023107481-A1 AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2023-06-15 WO disclosed
US-6306892-B1 ENZYME INHIBITORS HETEROCYCLIC AMIDES AGOURON PHARMACEUTICALS, INC. 2001-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11998610-B2 Conjugates and methods of using the same CD47, CD44, CD74 PPARA 3022/4885KLK7 2208/4885KLK5 2614/4885
US-20250059214-A1 AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS LONP1, ACAT1, ACAA2 PPARA 1372/4885KLK7 4446/4885KLK5 4114/4885
US-20240398966-A1 CONJUGATES AND METHODS OF USING THE SAME CD47, CD44, CD74 PPARA 3022/4885KLK7 2208/4885KLK5 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.